Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

Retinal Vein Occlusions after Use of Rofecoxib (VIOXX)

Meyer C. H.1, Gähler R.2, Schmidt J. C.1
Department of Ophthalmology1 and Department of Anesthesiology2, Philipps University Marburg

Purpose: After the use of rofecoxib (VIOXX), a nonsteroidal anti-inflammatory drug, a greater incidence of cardiovascular thrombotic events has been reported. Rofecoxib, a selective cyclooxygenase (COX)-2 inhibitor, may increase the platelet aggregation by inhibiting the thromboxane A2 production.
Method: We present two patients with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) by medical history, fluorescein angiography and fundus photography after application of rofecoxib.
Results: A 72-year-old female with rheumatoid arthritis was treated with rofecoxib. When the dosage was doubled to 50mg daily, she noticed a sudden painless decrease of vision in her right eye. Biomicroscopy OD demonstrated a CRVO with tortuous retinal veins and numerous flecked hemorrhages in the midperiphery. A 68 year-old female with severe osteoporosis developed a BRVO 1 day after taking rofecoxib (25mg) daily.
Conclusions: Although COX-2 inhibitors are safe in the majority of patients, they may induce prothrombortic effects under certain conditions. Few patients with predisposed thrombosis may be at risk for cardiovascular and ocular thrombotic events.


Zurück | Back